MDRX - Allscripts upgraded to buy at Argus on increasing margins Veradigm business

• Argus has upgraded Allscripts Healthcare Solutions ( NASDAQ: MDRX ) to buy from hold due to its growing Veradigm business and attractive valuation.
• The firm has a price target of $25 (35% upside based on Tuesday's close).
• Analyst David Coleman highlighted Allscripts' ( MDRX ) increasing margins and its Q3 results that beat expectations .
• He also mentioned that the Veradigm segment saw Q3 revenue of $145M, up from $137M in the year-ago period.
• "The company's cloud-based solutions have helped to meet the changing needs of patients and healthcare providers during the pandemic," he wrote.

For further details see: